CNSP — CNS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026
CNS Pharmaceuticals Inc expected to post a loss of $9.60 a share - Earnings Preview
CNS Pharmaceuticals Inc expected to post a loss of $9.60 a share - Earnings Preview
CNS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
CNS Pharmaceuticals Inc expected to post a loss of $9.66 a share - Earnings Preview
RCS - CNS Pharmaceuticals - CNS to Host Virtual Analyst & Investor Day
CNS Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Cortice Biosciences Reports 5.7% Stake In CNS Pharmaceuticals
Brief: CNS Pharma Expands Pipeline With In-License Of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane
Brief: Cns Pharmaceuticals Says On July 5, Received Letter From Nasdaq Notifying Co It Had Regained Compliance With Bid Price Rule
Brief: CNS Pharmaceuticals Files For Mixed Shelf Of Up To $75 Mln
Brief: Cns Pharmaceuticals Files Prospectus For Secondary Offering Of Up To 3.8 Million Shares Of Common Stock
Brief: Cns Pharmaceuticals says Cash On Hand And Cash Raised In Oct Sufficient To Fund Operations
Brief: Cns Pharmaceuticals Says Enrollment Of 229 Of Expected 243 Patients In Ongoing Study Evaluating Berubicin For Treatment Of Recurrent GBM
Brief: Cns Pharmaceuticals-On Aug 17, Received Letter From Nasdaq Which Notified Co That It Does Not Presently Comply With Nasdaq's Listing Rule 5550(B)(1)
Brief: Cns Pharmaceuticals Says Current Expectation Is That Cash On Hand, Is Sufficient To Fund Operations Beyond Interim Analysis And Into Q4 Of 2023